Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) has announced an upcoming oral presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, scheduled for March 16-19. The presentation will showcase the company's first-ever Phase 1 safety and pharmacokinetic data for their drug candidate SAT-3247.
The presentation, titled 'First-in-human Phase 1 study of orally administered SAT-3247 in healthy volunteers and adult participants with Duchenne Muscular Dystrophy (DMD),' will be delivered by Chief Scientific Officer Phil Lambert on Wednesday, March 19, 2025, at 8:00 AM CT in the Coronado ABCD room at the Hilton Anatole, Dallas. The presentation materials will be made available on the company's investor relations website following the session.
Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) ha annunciato una prossima presentazione orale alla Conferenza Clinica e Scientifica 2025 dell'Associazione per la Distrofia Muscolare (MDA) a Dallas, prevista per il 16-19 marzo. La presentazione mostrerà i dati di sicurezza e farmacocinetica della Fase 1 per il loro candidato farmaco SAT-3247.
La presentazione, intitolata 'Studio di Fase 1 per la prima volta su esseri umani dell'SAT-3247 somministrato per via orale a volontari sani e partecipanti adulti con Distrofia Muscolare di Duchenne (DMD),' sarà tenuta dal Direttore Scientifico Phil Lambert mercoledì 19 marzo 2025, alle 8:00 AM CT nella sala Coronado ABCD dell'Hilton Anatole, Dallas. I materiali della presentazione saranno resi disponibili sul sito web delle relazioni con gli investitori dell'azienda dopo la sessione.
Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) ha anunciado una próxima presentación oral en la Conferencia Clínica y Científica 2025 de la Asociación de Distrofia Muscular (MDA) en Dallas, programada para el 16-19 de marzo. La presentación mostrará los datos de seguridad y farmacocinética de Fase 1 para su candidato a fármaco SAT-3247.
La presentación, titulada 'Estudio de Fase 1 en humanos del SAT-3247 administrado por vía oral en voluntarios sanos y participantes adultos con Distrofia Muscular de Duchenne (DMD),' será presentada por el Director Científico Phil Lambert el miércoles 19 de marzo de 2025, a las 8:00 AM CT en la sala Coronado ABCD del Hilton Anatole, Dallas. Los materiales de la presentación estarán disponibles en el sitio web de relaciones con inversores de la empresa después de la sesión.
Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF)는 다가오는 2025 근위축성 측삭 경화증 협회(MDA) 임상 및 과학 회의에서 구두 발표를 할 것이라고 발표했습니다. 이 발표는 3월 16일부터 19일까지 달라스에서 진행됩니다. 발표에서는 그들의 약물 후보인 SAT-3247의 첫 번째 단계 1 안전성 및 약리학적 데이터가 공개됩니다.
'건강한 자원봉사자와 뒤셴 근육 이영양증(DMD) 성인 참가자에게 경구 투여된 SAT-3247의 첫 번째 인체 단계 1 연구'라는 제목의 발표는 수요일인 2025년 3월 19일 오전 8:00 CT에 달라스 힐튼 아나톨의 코로라도 ABCD 룸에서 과학 책임자 필 램버트에 의해 진행됩니다. 발표 자료는 세션 후 회사의 투자자 관계 웹사이트에서 제공될 예정입니다.
Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) a annoncé une prochaine présentation orale à la Conférence Clinique et Scientifique 2025 de l'Association de Dystrophie Musculaire (MDA) à Dallas, prévue du 16 au 19 mars. La présentation mettra en avant les données de sécurité et de pharmacocinétique de Phase 1 pour leur candidat médicament SAT-3247.
La présentation, intitulée 'Étude de Phase 1 chez l'homme du SAT-3247 administré par voie orale à des volontaires sains et à des participants adultes atteints de Dystrophie Musculaire de Duchenne (DMD),' sera présentée par le Directeur Scientifique Phil Lambert le mercredi 19 mars 2025, à 8h00 CT dans la salle Coronado ABCD de l'Hilton Anatole, Dallas. Les documents de présentation seront disponibles sur le site Web des relations avec les investisseurs de l'entreprise après la session.
Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) hat eine bevorstehende mündliche Präsentation auf der 2025 Konferenz der Muskulären Dystrophie Vereinigung (MDA) in Dallas angekündigt, die vom 16. bis 19. März stattfindet. Die Präsentation wird die ersten Sicherheits- und Pharmakokinetikdaten der Phase 1 für ihren Arzneimittelkandidaten SAT-3247 vorstellen.
Die Präsentation mit dem Titel 'Erste Phase-1-Studie bei Menschen mit oral verabreichtem SAT-3247 bei gesunden Freiwilligen und erwachsenen Teilnehmern mit Duchenne-Muskeldystrophie (DMD)' wird am Mittwoch, den 19. März 2025, um 8:00 Uhr CT im Coronado ABCD Raum des Hilton Anatole, Dallas, von Chief Scientific Officer Phil Lambert gehalten. Die Präsentationsmaterialien werden nach der Sitzung auf der Investor Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
- Satellos plans to highlight Phase 1 safety and PK data for SAT-3247
“The oral presentation at this year’s MDA conference is an exciting opportunity and significant development milestone for Satellos to showcase our first-ever Phase 1 data for SAT-3247,” said Frank Gleeson, Satellos Co-Founder and CEO.
Oral Presentation:
Title: First-in-human Phase 1 study of orally administered SAT-3247 in healthy volunteers and adult participants with Duchenne Muscular Dystrophy (DMD)
Date: Wednesday, March 19, 2025
Time: 08:00 AM CT
Location/Room: Coronado ABCD at the Hilton Anatole,
Presenter: Phil Lambert, Ph.D., Chief Scientific Officer, Satellos
A copy of the presentation will be available after the session on the Events & Presentations page located at: https://ir.satellos.com/events-and-presentations/default.aspx.
About Phase 1 Clinical Trial
The Phase 1 clinical trial is comprised of two components. In the first component, Phase 1a, 72 healthy volunteers have been enrolled in a blinded, randomized, placebo-controlled, staggered, parallel design study to assess the safety and pharmacokinetic properties of SAT-3247. Participants were randomized across five SAD cohorts, four MAD cohorts, and one food effect dose cohort. The second component, the Phase 1b portion of the trial, is currently ongoing. Up to 10 adult volunteers with genetically confirmed DMD will be enrolled in a 28-day, open-label, single dose cohort to assess safety and pharmacokinetic properties in patients and explore potential pharmacodynamic markers.
About SAT-3247
SAT-3247 is a proprietary, oral small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle which is lost in Duchenne muscular dystrophy (DMD or Duchenne) and other degenerative or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD, independent of dystrophin and regardless of exon mutation status.
About Satellos Bioscience Inc.
Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration in degenerative or injury conditions by correcting muscle stem cell polarity. Satellos has generated a body of preclinical evidence with SAT-3247 to support its discovery that correcting muscle stem cell polarity has the potential to restore skeletal muscle regeneration to repair and strengthen muscle that has degenerated or been damaged. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Additionally, Satellos is leveraging its breakthrough research and proprietary discovery platform MyoReGenX™, to identify additional degenerative muscle diseases or injury conditions where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development. For more information, visit www.satellos.com.
Notice on Forward-Looking Statements
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; the general benefits of modulating stem cell polarity by administering small molecule drugs; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; the utility of regenerating muscle by modulating polarity; and Satellos’ technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are “forward-looking information or statements.” Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective”, “assert” or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management’s ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the “Risk Factors” section of Satellos’ Annual Information Form dated March 26, 2024 (which is located on Satellos’ profile at www.sedarplus.ca). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218528261/en/
Investors: Liz Williams, CFO, ir@satellos.com
Media: Jessica Yingling, Ph.D., jessica@litldog.com
Clinical Trial Info: medicalinfo@satellos.com
Source: Satellos Bioscience Inc.
FAQ
When will Satellos (MSCLF) present their Phase 1 data for SAT-3247 at the 2025 MDA Conference?
What type of data will Satellos (MSCLF) present for SAT-3247 at the 2025 MDA Conference?
Where can investors access Satellos' (MSCLF) MDA Conference presentation materials?
What is the focus of Satellos' (MSCLF) SAT-3247 clinical trial?
